Search clinical trials for: veltuzumab

Total 481 results

West German Study Group
Merck Sharp & Dohme LLC; NanoString Technologies, Inc.

Completed

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (Keyriched-1)

Breast Cancer

Germany
Natalie Callendar
Bristol-Myers Squibb

Withdrawn

Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant (Immuno-POWER)

Multiple Myeloma
Hoffmann-La Roche

Completed

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Breast Cancer

Spain, United Kingdom, Belgium, Austria, Brazil, France, Germany, Hungary, Italy, Thailand, Korea, Republic of, Hong Kong, Romania, Canada, Argentina, Czechia, Peru, Estonia, Mexico, Poland, Russian Federation, Croatia, Netherlands
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer

China
Hoffmann-La Roche

Completed

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Solid Tumor

Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
Samsung Medical Center

Unknown

Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia

Acute Myeloid Leukemia

Korea, Republic of
Baylor College of Medicine
William Marsh Rice University

Active, not recruiting

Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (ATACC AML)

Acute Myeloid Leukemia

United States
Western Regional Medical Center

Terminated

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Neohttp)

HER2-positive Breast Cancer | ER-positive Breast Cancer

United States
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
Eli Lilly and Company
CoLucid Pharmaceuticals

Completed

Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration

Healthy

United States
M.D. Anderson Cancer Center

Recruiting

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Jonsson Comprehensive Cancer Center
University of California, Los Angeles; Pfizer; Jazz Pharmaceuticals

Terminated

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Acute Myelogenous Leukemia

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Breast Cancer

Italy, Korea, Republic of, Spain, Taiwan, United Kingdom, Brazil, Russian Federation, Thailand, Israel, Turkey, Austria, Canada, Poland, Sweden, Australia, Peru, Switzerland, Mexico
Carolyn Britten
Oncovir, Inc.

Completed

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

Metastatic Pancreatic Cancer

United States
The Netherlands Cancer Institute
Seagen Inc.

Recruiting

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (TRAIN-4)

Breast Cancer

Netherlands
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer (JOSHUA)

Gastric Cancer

France, Belgium, Korea, Republic of, Spain, Czechia, Germany, Italy, Netherlands
SCRI Development Innovations, LLC
Genentech, Inc.; Prometheus Laboratories

Completed

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Breast Cancer

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
University of Maryland, Baltimore
Genentech, Inc.

Terminated

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Metastatic Breast Cancer

United States
Raija Silvennoinen
Bristol-Myers Squibb; Amgen; Hospital District of Helsinki and Uusimaa

Completed

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines (KEd)

Multiple Myeloma in Relapse

Finland, Sweden
M.D. Anderson Cancer Center

Completed

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Acute Promyelocytic Leukemia

United States
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Genentech, Inc.
Roche Pharma AG

Completed

A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer (PENGUIN)

Non-Small Cell Lung Cancer

Australia, United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (PUFFIN)

Breast Cancer

China
Cinnagen

Completed

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

HER2-positive Breast Cancer

Iran, Islamic Republic of
Hoffmann-La Roche

Completed

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Solid Tumor

United Kingdom, Netherlands
Hoffmann-La Roche

Completed

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Spain, United Kingdom, Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Michelle Melisko

Terminated

Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+

Solid Tumor

United States
Alliance Foundation Trials, LLC.
Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaborators

Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

HER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia (AML-17)

Leukemia

France, Belgium, Netherlands, Italy, Portugal, Austria, Germany
M.D. Anderson Cancer Center

Completed

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
European Organisation for Research and Treatment...

Completed

Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Leukemia

France, Belgium, Netherlands, Germany, Italy, Austria, Croatia
German Cancer Research Center

Recruiting

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Early-stage Breast Cancer

Germany
Oslo University Hospital
Vestre Viken Hospital Trust; University Hospital of North Norway; Ostfold Hospital... and other collaborators

Recruiting

Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N)

Cancer Metastatic

Norway
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Leukemia

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer (TRAP-2)

Esophageal Cancer | Esophageal Adenocarcinoma

Netherlands
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer; HER2-positive; Metastatic

United States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
UNICANCER

Active, not recruiting

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status (NeoTOP)

Breast Cancer

France
George Albert Fisher
Genentech, Inc.

Terminated

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
West German Study Group
Roche Pharma AG

Recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT)

Breast Cancer

Germany
Dana-Farber Cancer Institute
Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation; Terri...

Active, not recruiting

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Breast Cancer

United States
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA)

Metastatic Breast Cancer

United States, Canada, China, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Spain, United Kingdom, Brazil, Guatemala, Japan, Russian Federation, Singapore, Thailand, Latvia, Argentina, Poland, Ecuador, Mexico, Croatia and more
Hoffmann-La Roche

Completed

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Breast Cancer

France, Spain, Denmark, Germany
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Breast Cancer

Sweden, Canada, South Africa, Spain, United Kingdom, Germany, Taiwan, Switzerland, New Zealand, Italy, Bosnia and Herzegovina, Serbia, Portugal, Greece, Romania, Brazil, Korea, Republic of, Mexico, Croatia, Bahamas
Hoffmann-La Roche

Completed

A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (VELVET)

Breast Cancer

France, United States, Denmark, Germany, Spain, Italy, Brazil
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland

Search clinical trials for: veltuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations